Biologics Contract Development Market Poised for Significant Growth, Projected to Reach USD 14 Billion by 2030

According to Next Move Strategy Consulting, Biologics Contract Development Market is forecasted to reach USD 14 billion by 2030, expanding at a compound annual growth rate (CAGR) of 9% from 2024 to 2030. The biologics contract development industry encompasses outsourcing services for pharmaceutical and biotech companies, focusing on biologics derived from living organisms. These services include cell line development, process development, analytical and bioanalytical testing, formulation, and regulatory support, enabling companies to navigate the complex and highly regulated drug development process.

Click Here for Your FREE Sample!

Market Growth Driven by Chronic Diseases and Demand for Biologics

The demand for biologics contract development services is significantly fueled by the rising prevalence of chronic diseases such as cancer, diabetes, cardiovascular disorders, and autoimmune conditions. According to the American Cancer Society, around 20 million cancer cases were diagnosed in 2022, with projections estimating an increase to 35 million cases by 2050. Biologics, being targeted therapies derived from living cells, offer more precise and effective treatment options for these diseases.

Additionally, the growing interest in exosome-based therapies for regenerative medicine, drug delivery, and cancer treatment has increased demand for specialized expertise in contract development organizations (CDOs). The launch of ExoXpert by EXO Biologics SA in February 2024 exemplifies the industry’s push toward addressing the lack of scalable exosome production and manufacturing capabilities.

Grab a FREE Sample Now

Segmentation and Regional Insights

The biologics contract development market is segmented based on product type, service type, end-user, and geography.

• By Product Type: Antibodies, cell therapies, vaccines, and others.
• By Service Type: Mammalian, microbial, and others.
• By End-User: Clinical, hospital, pharmaceutical, biotechnology, and others.
• By Geography: North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

North America Leads the Market:

North America holds the largest share of the biologics contract development market and is expected to maintain its dominance throughout the forecast period. The U.S., in particular, has witnessed a surge in spinal disorder cases, such as degenerative disc disease and spinal stenosis, increasing the demand for innovative biologic therapies.

According to the National Institutes of Health (NIH), approximately 17,000 new spinal cord injury cases are reported annually in the U.S., accounting for 38% of global cases. This demand has led pharmaceutical firms to collaborate with CDOs to accelerate the development of effective biologic therapies.

Additionally, the increasing availability of contract development and manufacturing services in the U.S. further fuels market growth. Companies such as Tanvex BioPharma USA Inc. have expanded their services with the launch of Tanvex CDMO in October 2023, offering comprehensive contract development and manufacturing solutions, including cell line and formulation development.

Key Industry Players and Strategic Developments

The biologics contract development market comprises several major players, including:

• AGC Biologics
• Boehringer Ingelheim
• Catalent
• Cell Therapies
• WuXi Biologics
• FUJIFILM Diosynth Biotechnologies
• KBI Biopharma
• Kemwell Biopharma
• Lonza
• Samsung Biologics

These companies are implementing strategies such as collaboration, innovation, and expansion to strengthen their market positions. For example, AGC Biologics launched the AGCellerate program in June 2023 to offer IND-ready GMP materials for monoclonal antibodies, lentiviral vectors, adeno-associated vectors, and pDNA materials. This initiative underscores the industry’s commitment to streamlining biologics development and expediting market entry for new therapies.

Investment Opportunities and Market Outlook

The biologics contract development market is ripe with investment opportunities, supported by:

• Rising healthcare expenditures worldwide, necessitating advanced biologic solutions.
• Increasing focus on personalized medicine, enhancing patient-specific treatment strategies.
• Technological advancements in biologic drug development, driving efficiency and scalability.

A detailed analysis of the market provides insights into key drivers, restraints, opportunities, and competitive dynamics. Additionally, value chain analysis offers a clear understanding of stakeholder roles within the industry.

About Next Move Strategy Consulting:

Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations within dusty experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical businessdecisions that enables them to move beyond time and have competitive edge in the industry.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

Summary

The global biologics contract development market is experiencing rapid expansion, fueled by the growing burden of chronic diseases, the increasing need for biologics, and technological advancements in contract development services. North America continues to dominate the industry, supported by a strong healthcare infrastructure and the rising prevalence of complex conditions requiring biologic therapies.

Industry players are focusing on strategic collaborations and expansions to maintain market leadership. As biologics continue to revolutionize modern medicine, contract development services will play a crucial role in bringing innovative treatments to patients worldwide. With an anticipated CAGR of 9% through 2030, the market presents lucrative opportunities for investors, pharmaceutical companies, and biotech firms aiming to leverage the growing demand for biologics development.